- Trials with a EudraCT protocol (68)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
68 result(s) found for: Therapeutic window.
Displaying page 1 of 4.
EudraCT Number: 2018-001988-23 | Sponsor Protocol Number: AEZS-130-P01 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Aeterna Zentaris GmbH | |||||||||||||
Full Title: Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/... | |||||||||||||
Medical condition: Diagnosis of Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002827-27 | Sponsor Protocol Number: EMI-137-CRC-001 | Start Date*: 2016-12-16 | |||||||||||
Sponsor Name:Edinburgh Molecular Imaging Ltd. | |||||||||||||
Full Title: A Phase IIb, Open Label Study for the Detection of Dysplastic Colorectal Polyps during Colonoscopy after EMI-137 Injection in Patients with High Suspicion of Colorectal Cancer. | |||||||||||||
Medical condition: Dysplastic Colorectal Polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000631-27 | Sponsor Protocol Number: NCT01778842 | Start Date*: 2014-01-28 | ||||||||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | ||||||||||||||||||
Full Title: PhaRmacodynamic Effect of antiplatelet agents in elderly patients: Standard clopidogrel versus prasugrEl low dose Therapy. | ||||||||||||||||||
Medical condition: Patients over 75 years with acute coronary syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003374-10 | Sponsor Protocol Number: TOC106489 | Start Date*: 2007-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated... | ||
Medical condition: Uncomplicated skin and skin structure infections | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002547-25 | Sponsor Protocol Number: ARC1779-003 | Start Date*: 2007-12-19 | ||||||||||||||||
Sponsor Name:Archemix Corp. | ||||||||||||||||||
Full Title: A Phase 2 Study of an Aptameric von Willebrand Factor Antagonist, ARC1779, in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention | ||||||||||||||||||
Medical condition: ACS Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention (ST segemnt elevation MI and Non ST segemtn elevation MI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000563-41 | Sponsor Protocol Number: IMIMFTCL/GH/4 | Start Date*: 2014-08-08 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
Full Title: Recombinant hGH Biomarkers Discovery | ||
Medical condition: Healthy volunteers. There is not intended indication. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002782-38 | Sponsor Protocol Number: Gastro052011 | Start Date*: 2012-07-06 |
Sponsor Name:INFAI GmbH | ||
Full Title: Gastromotal 13C-octanoic acid breath test in the diagnosis and evaluation of therapeutic outcome in patients with dyspeptic symptoms and delayed gastric emptying | ||
Medical condition: Patients with dyspeptic symptoms and delayed gastric emptying. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007973-19 | Sponsor Protocol Number: VORI-ZonMW | Start Date*: 2009-04-09 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Pharmacologic optimization of voriconazole - a prospective clustered group-randomized cross-over trial of therapeutic drug monitoring | ||
Medical condition: The objective of this prospective stratified cluster randomized cross-over trial is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) res... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016601-42 | Sponsor Protocol Number: F60002 IN 202 G0 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prio... | |||||||||||||
Medical condition: Acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005101-12 | Sponsor Protocol Number: AGO-OVAR27 | Start Date*: 2021-11-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGO Research GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001345-32 | Sponsor Protocol Number: P07755 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp, a Subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) ES (Completed) CZ (Completed) SE (Completed) AT (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) LT (Prematurely Ended) EE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003236-23 | Sponsor Protocol Number: V503-049 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-li... | |||||||||||||
Medical condition: Oral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004137-91 | Sponsor Protocol Number: Gesida92016 | Start Date*: 2018-01-23 | |||||||||||
Sponsor Name:Fundacion SEIMC-GESIDA | |||||||||||||
Full Title: A single-arm, open-label, multicenter phase IV trial to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alfa-namide as first-line treatment in naïve patien... | |||||||||||||
Medical condition: AIDS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004834-26 | Sponsor Protocol Number: 2017-12 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:Albert Schweitzer hospital | |||||||||||||
Full Title: Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-006118-17 | Sponsor Protocol Number: B3I105940 | Start Date*: 2006-08-17 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome | ||
Medical condition: Irritable Bowel Syndrome (IBS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000906-12 | Sponsor Protocol Number: AQX-1125-301 | Start Date*: 2016-09-07 | ||||||||||||||||
Sponsor Name:Aquinox Pharmaceuticals (Canada) Inc. | ||||||||||||||||||
Full Title: The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targ... | ||||||||||||||||||
Medical condition: Interstitial Cystitis/Bladder Pain Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) LV (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004446-29 | Sponsor Protocol Number: LIBERAL-Trial | Start Date*: 2017-10-30 | |||||||||||
Sponsor Name:University Hospital Wuerzburg, Institution under public law, represented by the Medical Director | |||||||||||||
Full Title: Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients | |||||||||||||
Medical condition: Elderly patients (>= 70 years) undergoing intermediate- or high-risk non-cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002250-24 | Sponsor Protocol Number: GCAR-7213 | Start Date*: 2021-12-07 | |||||||||||
Sponsor Name:Global Coalition for Adaptive Research | |||||||||||||
Full Title: GCAR-7213: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Di... | |||||||||||||
Medical condition: Oncology - Glioblastoma (GBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FR (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003592-19 | Sponsor Protocol Number: NEOPAX-001 | Start Date*: 2012-12-11 |
Sponsor Name:CUB Erasme Hospital | ||
Full Title: Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or met... | ||
Medical condition: Resectable (cohort 1) and locally advanced or metastatic (cohort 2) pancreatic ductal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
